Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose

Hematological Oncology

Volumn 28, Issue 2, 2010, Pages 89-92

  Breccia, Massimo ^a   Cannella, Laura ^a   Stefanizzi, Caterina ^a   Latagliata, Roberto ^a   Nanni, Mauro ^a   Diverio, Daniela ^a   Santopietro, Michelina ^a   Federico, Vincenzo ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chronic myeloid leukaemia; Compliance; Cytogenetic responses; Imatinib

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FUSION PROTEINS, BCR-ABL; HEMATOLOGIC DISEASES; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; RISK; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77953250484     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.920     Document Type: Article

References (11)

1. Kantarjian H, Cortes J. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukaemia: using guidelines to make rational treatment choices. J Natl Compr Canc Netw 2008; 2 (suppl): 37-42.
2. O'Brien SG, Guilhot F, Goldman JM, et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood 2008; 112: abstr 186
3. Kobayashi S, Kimura F, Kobayashi A, Sato K, Motoyoshi K. Efficacy of low-dose imatinib in chronic phase chronic myelogenous leukaemia patients. Ann Hematol 2008; 88: 311-315.
4. Park SJ, Choi IK, Seo HY, et al. Reduced dose of imatinib for patients with chronic myeloid leukaemia and low body surface area. Acta Haematol 2007; 118: 219-221.
5. Carella AM, Lerma E. Durable responses in chronic myeloid leukaemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission. Ann Hematol 2007; 86: 749-752.
6. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006; 108: 1809-1820.
7. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-825.
8. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukaemia - a Europe against cancer program. Leukemia 2003; 17: 2318-2357.
9. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 2001; 344: 1031-1037.
10. Forrest DL, Trainor S, Brinkman RR, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leucemia are correlated with Sokal risk scoress and duration of therapy but not trough imatinib plasma levels. Leuk Res 2009; 33: 271-275.
11. Ishikawa I, Kato C, Harigae H, et al. 2006; Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia. Tohoku J Exp Med 210: 355-363.